EP Patent

EP3038616B1 — Methods for treating bacteremia and osteomyelitis using oritavancin

Assigned to Melinta Subsidiary Corp · Expires 2023-04-05 · 3y expired

What this patent protects

Patent listed against oritavancin-diphosphate.

Drugs covered by this patent

oritavancin-diphosphate (ORITAVANCIN DIPHOSPHATE)

Patent Metadata

Patent number: EP3038616B1
Jurisdiction: EP
Classification: —
Expires: 2023-04-05
Drug substance claim: No
Drug product claim: No
Assignee: Melinta Subsidiary Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.